**Company Overview**

**Industry Sector:** Pharmaceuticals

**Company Overview:** PharmaIN is a privately held injectable drug delivery company focused on the development of its family of unique formulation technologies for peptides, proteins, and potent small molecules. Our expertise lies in formulation development and intellectual property. PharmaIN is based in Seattle, WA and shares core facilities with the Pacific Northwest Diabetes Research Institute.

**Target Market(s):** Therapeutics

---

**Key Value Drivers**

**Technology**: The Protected Graft Copolymer (PGC™) is an injectable drug delivery system providing the benefits of PEGylation without chemical modification of the drug payload. The PGC nanocarrier extends the half-life of peptides, proteins, and potent small molecules without affecting the potency of the drug, while also providing targeting capabilities and the flexibility of IV or SubQ administration. PharmaIN’s most advanced programs are its PGC GLP-1 formulation for type 1 diabetes, and a small protein formulation against MRSA infection.

**Competitive Advantage:** The PGC technology distinguishes itself from other injectable drug formulation technologies by:
- Extending circulation time in the blood
- Retaining the chemical structure of the native drug
- Passively accumulating in inflamed and infected tissue, and solid tumors
- Improving the stability and solubility of drugs
- Enabling previously unfeasible biomolecules as therapeutics

**Plan & Strategy:** seeking development partners and fee-for-service customers

---

**Management**

**Leadership:**
John Presutti, CEO
Elijah Bolotin, President and Founder
Gerry Castillo, Director, Research and Development and Intellectual Property

**Scientific Advisory Board:**
Yechezkel Barenholz, PhD: Professor of Biochemistry, The Hebrew University-Hadassah Medical School
Alexei A. Bogdanov, Jr., PhD: Professor of Radiology and Cell Biology, University of Massachusetts Medical School
Stephen Lippard, PhD: Professor Chemistry, Massachusetts Institute of Technology
Riccardo Perfetti, MD, PhD: Medical Director and Global Development Leader, Department of Medical Sciences, Amgen, Inc. and Associate Professor of Medicine, University of California at Los Angeles

---

**Product Pipeline**

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
<th>R&amp;D</th>
<th>Pre-clinical</th>
<th>Clinical</th>
</tr>
</thead>
<tbody>
<tr>
<td>PGC GLP-1</td>
<td>Type 1 Diabetes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGC Anti-MRSA (small protein)</td>
<td>Acute MRSA infection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGC Insulin</td>
<td>Type 1 Diabetes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Undisclosed peptide</td>
<td>Liver Cirrhosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGC EGF-Gastrin</td>
<td>Type 1 Diabetes</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>